1. Home
  2. FPI vs ALLO Comparison

FPI vs ALLO Comparison

Compare FPI & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Farmland Partners Inc.

FPI

Farmland Partners Inc.

HOLD

Current Price

$11.79

Market Cap

490.8M

Sector

Real Estate

ML Signal

HOLD

Logo Allogene Therapeutics Inc.

ALLO

Allogene Therapeutics Inc.

HOLD

Current Price

$2.44

Market Cap

539.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FPI
ALLO
Founded
2013
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
490.8M
539.4M
IPO Year
2013
2018

Fundamental Metrics

Financial Performance
Metric
FPI
ALLO
Price
$11.79
$2.44
Analyst Decision
Hold
Strong Buy
Analyst Count
1
12
Target Price
N/A
$8.73
AVG Volume (30 Days)
386.6K
7.6M
Earning Date
05-06-2026
05-12-2026
Dividend Yield
3.08%
N/A
EPS Growth
N/A
34.09
EPS
0.61
N/A
Revenue
$52,178,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$144,130.60
P/E Ratio
$19.16
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.37
$0.86
52 Week High
$13.23
$4.46

Technical Indicators

Market Signals
Indicator
FPI
ALLO
Relative Strength Index (RSI) 55.59 48.36
Support Level $10.84 $2.14
Resistance Level $12.35 $2.71
Average True Range (ATR) 0.22 0.34
MACD 0.08 0.02
Stochastic Oscillator 91.79 8.85

Price Performance

Historical Comparison
FPI
ALLO

About FPI Farmland Partners Inc.

Farmland Partners Inc owns and seeks to acquire high-quality farmland throughout North America. The company is an internally managed real estate company which owns and contracts farmland and storage facilities located across the United States. Majority of the properties in its portfolio are used to grow primary crops, such as corn, soybeans, wheat, rice and cotton, and rest to produce specialty crops, such as almonds, pictachios, citrus, avacados, strawberies, and edible beans. The company generates its revenues through the rent it receives from its tenants.

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

Share on Social Networks: